Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Paragon 28 Inc FNA

Paragon 28, Inc. is a medical device company focused on the foot and ankle orthopedic market. The Company provides orthopedic solutions, procedural approaches and instrumentation that cover a range of foot and ankle ailments, including fracture fixation, forefoot, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, Charcot foot and orthobiologics. To treat these painful... see more

NYSE:FNA - Post Discussion

Paragon 28 Inc > Overweight Recommendation Issued On FNA By Piper Sandler
View:
Post by whytestocks on Aug 09, 2024 8:02pm

Overweight Recommendation Issued On FNA By Piper Sandler

Breaking News: $FNA Overweight Recommendation Issued On FNA By Piper Sandler2024-08-09 10:15:07 ET Piper Sandler analyst issues OVERWEIGHT recommendation for FNA on August 9, 2024 08:25AM ET. The previous analyst recommendation was Overweight. FNA was trading at $6.92 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...FNA - Overweight Recommendation Issued On FNA By Piper Sandler
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities